At AstraZeneca, we aim to transform the treatment of respiratory disease with our growing portfolio of inhaled and biologics medicines, along with scientific research focused on three key areas: lung immunity, lung epithelium and lung regeneration. We are excited to join clinicians, researchers and scientists at the 2017 European Respiratory Society (ERS) International Congress to share the latest in respiratory science advancements.
Follow us on Twitter @AstraZeneca and join the conversation using #ERSCongress.
Veeva ID: Z4-6489
Date of next review: May 2018